Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.69 |
| ▸ | MEN1 | O00255 | 6/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | GLA | P06280 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.51 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30307374 | 1.00 | KMT2A (0.69) | KMT2AMEN1RAB9AALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL7461797 | 0.98 | KMT2A (0.68) | KMT2AMEN1RAB9AALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL18095065 | 0.98 | KMT2A (0.68) | KMT2AMEN1RAB9AALDH1A1MAPT | |
| Acridine SCHEMBL28057414 | 0.98 | KMT2A (0.68) | KMT2AMEN1RAB9AALDH1A1MAPT | |
| Ammonia Solution, Strong SCHEMBL27885667 | 0.98 | KMT2A (0.68) | KMT2AMEN1RAB9AALDH1A1MAPT | |
| Acridine SCHEMBL27545385 | 0.85 | RAB9A (0.63) | KMT2AMEN1RAB9AALDH1A1MAPT | |
| SCHEMBL153507 | 0.82 | KMT2A (0.60) | KMT2AMEN1RAB9AALDH1A1MAPT | |
| SCHEMBL11061940 | 0.80 | ALDH1A1 (0.50) | KMT2AMEN1RAB9AALDH1A1MAPT | |
| SCHEMBL9735773 | 0.79 | ALDH1A1 (0.69) | KMT2AMEN1RAB9AALDH1A1MAPT | |
| SCHEMBL11333926 | 0.79 | KMT2A (0.64) | KMT2AMEN1RAB9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 774 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119894893-A | Sulfone substituted pyrido [3,4-D ] pyrimidine derivatives for the treatment of cancer | 拜耳公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119838022-A | Amatoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-118557747-A | Conjugates of cell binding molecules and camptothecin analogs | 杭州多禧生物科技有限公司 | 2024-08-30 | — | — | CN | claimed |
| CN-118451106-A | Combination therapy of Claudin 18.2 antagonists and PD-1/PD-L1 axis inhibitors | 苏州创胜医药集团有限公司 | 2024-08-06 | — | — | CN | claimed |
| CN-118434765-A | BCMA monoclonal antibodies and antibody-drug conjugates | 杭州多禧生物科技有限公司 | 2024-08-02 | — | — | CN | claimed |
| CN-118215676-A | Specific conjugation of antibody drug conjugates | 杭州多禧生物科技有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-117500507-A | Phosphorus derivatives as novel SOS1 inhibitors | 拜耳公司 | 2024-02-02 | — | — | CN | claimed |
| CN-117244076-A | Conjugates comprising self-degrading groups and methods related thereto | 乐高化学生物科学股份有限公司 | 2023-12-19 | — | — | CN | claimed |
| CN-116999571-A | Antibody-drug conjugates comprising anti-B7-H3 antibodies | 尹图赛利有限公司 | 2023-11-07 | — | — | CN | claimed |
| CN-116806157-A | Linker-payload and conjugates thereof | 芬兰吉利科斯有限公司 | 2023-09-26 | — | — | CN | claimed |
| US-20050043233-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-24 | — | — | US | claimed |
| US-20040245105-A1 | Electrolyte solution for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORPORATION (JP) | 2004-12-09 | — | — | US | claimed |
| WO-2004096224-A2 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-11 | — | — | WO | claimed |
| CN-1529892-A | Electrolyte for driving electrolytic capacitor and electrolytic capacitor | 如碧空株式会社 | 2004-09-15 | — | — | CN | claimed |
| EP-1437749-A1 | ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR | Rubycon Corporation (JP) | 2004-07-14 | — | — | EP | claimed |
| EP-1261325-A2 | NITROACRIDINE/TUMOR INHIBITOR COMPOSITIONS | NEW YORK MEDICAL COLLEGE (US) | 2002-12-04 | — | — | EP | claimed |
| EP-1257538-A2 | 9-ALKYLAMINO-1-NITROACRIDINE DERIVATIVES | NEW YORK MEDICAL COLLEGE (US) | 2002-11-20 | — | — | EP | claimed |
| US-20020037831-A1 | 1-Nitroacridine/tumor inhibitor compositions | TIWARI RAJ (US) | 2002-03-28 | — | — | US | claimed |
| WO-2001060801-A2 | 9-ALKYLAMINO-1-NITROACRIDINE DERIVATIVES | NEW YORK MEDICAL COLLEGE (US) | 2001-08-23 | — | — | WO | claimed |
| WO-2001060351-A2 | NITROACRIDINE/TUMOR INHIBITOR COMPOSITIONS | NEW YORK MEDICAL COLLEGE (US) | 2001-08-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037831-A1 | 1-Nitroacridine/tumor inhibitor compositions | MKI67, DIAPH1, API5 | KMT2A 2779/4885MEN1 369/4885RAB9A 3078/4885 |
| US-20050043233-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BAX, BCL2, CXCL12 | KMT2A 4366/4885MEN1 759/4885RAB9A 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.